亚美尼亚未接种疫苗女性人乳头瘤病毒感染负担:一系列基于人群的横断面患病率调查
在亚美尼亚2017年启动四价人乳头瘤病毒(HPV)疫苗接种规划后,针对未接种疫苗女性开展两项横断面患病率调查:尿液调查纳入17-21岁女性2485人,细胞学调查纳入21-39岁女性3017人,并收集宫颈癌样本评估高危HPV型别归因比例。结果显示任何HPV阳性率分别为4.5%和18%,高危HPV阳性率分别为2.9%和11%,HPV16/18阳性率分别为1.2%和3.3%;宫颈癌中HPV16/18占高危HPV感染的71%。
要点
- 尿液调查中17-21岁女性任何HPV阳性110人(4.5%),高危HPV 72人(2.9%),HPV16/18 29人(1.2%)。
- 细胞学调查中21-39岁女性任何HPV阳性553人(18%),高危HPV 326人(11%),HPV16/18 99人(3.3%)。
- 宫颈癌系列中HPV16/18占高危HPV感染的71%,HPV31/33/45/52/58占18%,其余高危型占11%。
核心结论
- 研究结果提供了亚美尼亚城市地区未接种疫苗年轻和成年女性HPV感染及未来宫颈癌负担的概况,可为情境特异性疫苗接种和筛查政策提供信息。
研究设计与样本
- 在未接种疫苗的女性出生队列中开展两项横断面HPV患病率调查:尿液调查针对17-21岁女性,细胞学调查针对21-39岁女性;另收集宫颈癌病例实验室样本以评估高危HPV型别归因比例。
主要发现
- 尿液调查纳入2485名女性,任何HPV阳性110人(4.5%),高危HPV 72人(2.9%),HPV16/18 29人(1.2%)。
- 细胞学调查纳入3017名女性,任何HPV阳性553人(18%),高危HPV 326人(11%),HPV16/18 99人(3.3%)。
- 宫颈癌系列中HPV16/18占所有高危HPV感染的71%,HPV31、33、45、52和58额外占18%,其余高危型占11%。
- 20-24岁、25-34岁和35-44岁年龄组对应的预测10年宫颈癌累积发病率分别为0.3%、1.3%和3.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2017, Armenia introduced a national human papillomavirus (HPV) vaccination programme with a quadrivalent vaccine at age 14 years. Successful implementation of the programme was affected by social media campaigns aiming to discredit its efficacy and safety, the COVID-19 pandemic, and local armed conflicts. To support national public health stakeholders, we initiated a series of studies to provide local evidence on the burden of HPV infection. METHODS: Two cross-sectional HPV prevalence surveys among unvaccinated birth-cohorts of women were conducted: a urine-based survey (UBS) targeted women aged 17-21 years, and a cell-based survey (CBS) targeted women aged 21-39 years. In addition, we collected a series of invasive cervical cancer (CC) case laboratory samples to assess the attributable proportion of high-risk (HR) HPV types to estimate the impact of HPV vaccination in Armenia. FINDINGS: In the UBS and the CBS, 2485 and 3017 women were included, respectively. In the UBS, 110 (4.5 %) women were positive for any HPV type, 72 (2.9 %) of which were HR HPV and 29 (1.2 %) were HPV16/18. In the CBS, 553 (18 %) were positive for any HPV type, 326 (11 %) of which were HR HPV, and 99 (3.3 %) were HPV16/18. In the CC series, HPV16/18 accounted for 71 % of all HR HPV infections, HPV 31, 33, 45, 52, and 58 accounted for an extra 18 %. The remaining HR types accounted for 11 % of all CC infected by HR HPV. The corresponding predicted cumulative 10-year CC incidence among 20-24, 25-34, and 35-44-year age group, was 0.3 %, 1.3 %, and 3.8 %, respectively. INTERPRETATION: Our findings provide a picture of the HPV infection and future cervical cancer burden among unvaccinated young and adult women in urban areas of Armenia and can inform context-specific vaccination and screening policies.
引用
- Baussano I, Tenet V, Baghdasarova K, et al. HPV burden in Armenia among unvaccinated women: a series of cross-sectional population-based prevalence surveys. Vaccine. 2025. PMID: 40627870. doi:10.1016/j.vaccine.2025.127405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。